369 related articles for article (PubMed ID: 32867307)
1. MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections.
Sethiya JP; Sowards MA; Jackson M; North EJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867307
[TBL] [Abstract][Full Text] [Related]
2. Efflux Pump Inhibitors Against Nontuberculous Mycobacteria.
Rindi L
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545436
[TBL] [Abstract][Full Text] [Related]
3. Controlling Extra- and Intramacrophagic
Viljoen A; Herrmann JL; Onajole OK; Stec J; Kozikowski AP; Kremer L
Front Cell Infect Microbiol; 2017; 7():388. PubMed ID: 28920054
[No Abstract] [Full Text] [Related]
4. MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections.
Li W; Yazidi A; Pandya AN; Hegde P; Tong W; Calado Nogueira de Moura V; North EJ; Sygusch J; Jackson M
Front Microbiol; 2018; 9():1547. PubMed ID: 30042757
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.
Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ
Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892
[TBL] [Abstract][Full Text] [Related]
6. Nontuberculous mycobacteria infections in immunosuppressed hosts.
Henkle E; Winthrop KL
Clin Chest Med; 2015 Mar; 36(1):91-9. PubMed ID: 25676522
[TBL] [Abstract][Full Text] [Related]
7. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
[TBL] [Abstract][Full Text] [Related]
8. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.
van Ingen J; Boeree MJ; van Soolingen D; Mouton JW
Drug Resist Updat; 2012 Jun; 15(3):149-61. PubMed ID: 22525524
[TBL] [Abstract][Full Text] [Related]
9. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
10. Treatment of slowly growing mycobacteria.
Philley JV; Griffith DE
Clin Chest Med; 2015 Mar; 36(1):79-90. PubMed ID: 25676521
[TBL] [Abstract][Full Text] [Related]
11. Medications and monitoring in nontuberculous mycobacteria infections.
Egelund EF; Fennelly KP; Peloquin CA
Clin Chest Med; 2015 Mar; 36(1):55-66. PubMed ID: 25676519
[TBL] [Abstract][Full Text] [Related]
12. Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.
Fay A; Czudnochowski N; Rock JM; Johnson JR; Krogan NJ; Rosenberg O; Glickman MS
mBio; 2019 Jun; 10(3):. PubMed ID: 31239378
[TBL] [Abstract][Full Text] [Related]
13. The Antimalarial Mefloquine Shows Activity against
Degiacomi G; Chiarelli LR; Recchia D; Petricci E; Gianibbi B; Fiscarelli EV; Fattorini L; Manetti F; Pasca MR
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445239
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.
Aguilar-Ayala DA; Cnockaert M; André E; Andries K; Gonzalez-Y-Merchand JA; Vandamme P; Palomino JC; Martin A
J Med Microbiol; 2017 Aug; 66(8):1140-1143. PubMed ID: 28749330
[TBL] [Abstract][Full Text] [Related]
15. Identification and drug susceptibility testing for nontuberculous mycobacteria.
Huang WC; Yu MC; Huang YW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S32-S41. PubMed ID: 32423573
[TBL] [Abstract][Full Text] [Related]
16. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
17. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.
Brown-Elliott BA; Woods GL
J Clin Microbiol; 2019 Oct; 57(10):. PubMed ID: 31315954
[TBL] [Abstract][Full Text] [Related]
18. NTM drug discovery: status, gaps and the way forward.
Wu ML; Aziz DB; Dartois V; Dick T
Drug Discov Today; 2018 Aug; 23(8):1502-1519. PubMed ID: 29635026
[TBL] [Abstract][Full Text] [Related]
19. The treatment of rapidly growing mycobacterial infections.
Kasperbauer SH; De Groote MA
Clin Chest Med; 2015 Mar; 36(1):67-78. PubMed ID: 25676520
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic treatment for nontuberculous mycobacterial lung disease.
Kang YA; Koh WJ
Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
